Is augmentation of PORH by rosuvastatin adenosine-receptor mediated?

Phase 4

Completed

• Conditions: ischemie; Heart infarction; Ischaemia; 10011082; 10003216

• Registration Number: NL-OMON32791
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 8

Inclusion Criteria

Healthy volunteers, 18-50 years of age

Exclusion Criteria

History of any cardiovascular disease
Hypertension (in supine position: systole >140 mmHg, diastole >90 mmHg)
Diabetes Mellitus (fasting glucose >7.0 mmol/L or random glucose >11.0 mmol/L)
Hyperlipidemia (fasting total cholesterol >5.5 mmol/L or random total cholesterol >6.5 mmol/L)
Alanine amino transferase >90 U/L
Creatin kinase >440 U/L
Raised rabdomyolysis risk
GFR <80 ml/min
overt clinical signs of hypothyroidism
Myopathy in family history
Alcohol abuse
Concomitant chronic use of medication
Participation to any drug-investigation during the previous 60 days as checked with VIP check according to CRCN standard procedures.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Forearm blood flow (FBF) will be measured as an indicator for post occlusive<br /><br>reactive hyperaemia (PORH). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>effect of 7 day treatment with rosuvastatin on lipid profile</p><br>